Because individuals who carry the APOE e4 gene variant show up to have a larger hazard of serious troubles, the FDA recommends staying tested for the gene variant before beginning treatment with lecanemab or donanemab.Mild cognitive impairment is significant to recognize since it will increase someone’s risk of building dementia — together with